News G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Delayed Nasdaq Other stock markets 03:48:22 2024-04-18 pm EDT			5-day change	1st Jan Change
4.15 ^USD	-3.04%		-11.54%	+35.74%

Feb. 28	G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 28	Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024	Apr. 17	AQ
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 04	AQ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 01	AQ
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	Mar. 04	AQ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 01	AQ
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	Feb. 28	MT
Transcript : G1 Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $14.9M	Feb. 28	MT
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 28	CI
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	Feb. 28	GL
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 27	AQ
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024	Feb. 15	AQ
Top Midday Decliners	Feb. 13	MT
Caution Ahead of Key Inflation Data Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	Feb. 13	MT
Needham Adjusts G1 Therapeutics Price Target to $12 From $14, Maintains Buy Rating	Feb. 13	MT
G1 Therapeutics Gets Nod for Continuing Breast Cancer Study But CEO Notes Lack of 'Positive Interim Analysis'; Shares Drop Premarket	Feb. 13	MT
Wedbush Adjusts G1 Therapeutics' PT to $4 From $5, Keeps Outperform Rating	Feb. 13	MT
G1 Therapeutics Gets Continuation Recommendation From Data Monitoring Committee for Phase 3 Breast Cancer Study	Feb. 13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Summary

Filters